VES-001 is under clinical development by Vesper Bio and currently in Phase I for Frontotemporal Dementia (FTD). According to GlobalData, Phase I drugs for Frontotemporal Dementia (FTD) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VES-001 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VES-001 overview

VES-001 is under development for the treatment of frontotemporal dementia (FTD). It is administered through oral route. The drug candidate acts by targeting sortilin (SORT1).

Vesper Bio overview

Vesper Bio is a biotechnology company developing first-in-class small molecule Vps10p modulators to target various therapeutic indications.

For a complete picture of VES-001’s drug-specific PTSR and LoA scores, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.